# iTHYM (NCT06750952)

> Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06750952
- Phase: PHASE2
- Status: NOT_YET_RECRUITING
- Sponsor: Sun Yat-sen University
- Conditions: Relapsed or Metastatic Thymic Cancer; First-line Treatment
- Interventions: Ivonescimab Combined With Chemotherapy
- Enrollment: 24
- Primary outcome: Progression free survival at 6 months（PFS 6m）

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ithym-nct06750952